Table III.
Overall adjusted cause-specific hazard ratios (HRs) for switching to an angiotensin-II receptor blocker after angiotensin converting enzyme inhibitor therapy, stratified by British Thoracic Society asthma treatment step∗
| British Thoracic Society asthma treatment step | With asthma, n (%) | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted P |
|---|---|---|---|---|---|
| Age ≥60 y | |||||
| ≥3 | 9057 (45.6) | 1.47 (1.44-1.51) | <.001 | 1.35 (1.32-1.39) | <.001 |
| 2 | 5774 (29.1) | 1.22 (1.18-1.26) | <.001 | 1.13 (1.09-1.17) | <.001 |
| 1 | 5026 (25.3) | 1.23 (1.19-1.28) | <.001 | 1.14 (1.09-1.19) | <.001 |
| Age <60 y | |||||
| ≥3 | 9398 (44.6) | 1.27 (1.23-1.30) | <.001 | 1.18 (1.15-1.22) | <.001 |
| 2 | 4982 (23.6) | 1.09 (1.05-1.14) | <.001 | 1.02 (0.96-1.07) | .753 |
| 1 | 6716 (31.8) | 0.97 (0.94-1.01) | .193 | 0.96 (0.92-1.00) | .146 |
CI, confidence interval.
∗
Model was adjusted for sex, age, body mass index, smoking status, history of hypertension, history of cardiovascular disease, chronic obstructive pulmonary disease, and socioeconomic deprivation.